We describe an immunohistochemical technique that makes use of two monoclonal antibodies (MAb), one to detect the transformkg growth factor B (TGFB) and another that reacts with iodo-and bmmod&dine.
Introduction
An ongoing search for mechanisms that control the proliferation and differentiation of neoplastic cells has unraveled new and exciting areas in cancer research. One of these avenues is populated by a variety of growth factors which have served the dual role of clarifying as well as further complicating our understanding of the biological basis of cell growth in human cancers (1,2). One such important group is that of the transforming growth factors (TGF). This family of alpha and beta polypeptides derives its name from the fact that medium conditioned by these proteins, which were originally isolated from a murine sarcoma virus-transformed cell line, supported the growth of anchorage-dependent cells (3) . However, it is now evident that despite their name these growth factors also play an essential role in controlling proliferation and differentiation of cells under normal physiological conditions (4).
A study on human tissues was undertaken to define the relationship of TGFB expression and proliferation of malignant cells in situ, as described below. Since tissues from cancer patients are more readily available for studies than those from normal subjects, our hope was to acquire some appreciation of both by characterizing the former.
Our group has used in vivo infusions of the thymidine analogues iododeoxyuridine (IUdR) and bromodeoxyuridine (BrdU) as DNA labels, to investigate the cycling properties of malignant cells in a variety of human cancers (5,6). We routinely embed these tissues in plastic using glycol methacrylate and then treat the sections with monoclonal antibodies (MAb) against IUdR and BrdU as described previously (6) to determine the labeling index (U), duration of S-phase (Ts), and the total cell cycle time (Tc) of malignant cells. To examine the geographic relationship of these dividing cells with various growth factors in situ, we developed a dual labeling method that is reliable and easy to accomplish in plastic-embedded tissue. This report describes our novel method, which represents the combination of a modified immunohistochemical procedure published by Fava et al. (7) to detect the TGF family of growth factors and simultaneous labeling for IudRIBrdU. We expect that the ability to assess the presence of growth factors and the behavior of target cells present in their vicinity will contribute significantly towards a better understanding of the dynamic relationship between cancer cells and their microenvironment.
Materials and Methods
The IUdR/BrdU protocols were reviewed and approved by the Institutional Review Board of the University of Cincinnati Medical Center as well as by the National Cancer Institute and the Food and Drug Administration. The IUdR and/or BrdU for these studies were supplied by the NCI. Informed consent was obtained from every patient before the administration of BrdU and IUW.
S-phase cells from various types of solid tumors, such as brain, breast, lymphoma, gastrointestinal cancers, acute myeloid leukemia (AML) and
myelodysplvtic syndrome (MDS), were labeled using intravenous IUdR and BrdU. Immediately after the infusion ended tumors were resected or biopsy specimens were obtained. All tissues were fixed in Bouin's solution and embedded in glycol methacrylate. Two to three-pm thick sections were obtained and placed on alcian blue-coated coverslips (6) . Simultaneous labeling for TGFB and IUdRIBrdU. The sections were then labeled for TGFB as follows. After the tissues were rehydrated in distilled water for 10 min, they were incubated with freshly diluted 3% H202 for 30 min and then with pronase (1 mgll ml; Calbiochem, LaJolla, CA) for 45 min. Specimenswere rinsed thoroughly with 0.15 M (0.15 M sodium chloride in 0.10 M phosphate buffer, pH 7.5) PBS after each incubation. After the last 0.15 M PBS rinse they were placed in 0.5 M (0.5 M sodium chloride in 0.10 M phosphate buffer, pH 7.5) PBS for 15 min.
The samples were then incubated with monoclonal anti-TGFB3 (Oncogene Science; Manhasset, NY) diluted 1:lOO (1 pgglml) in 0.5 M PBS containing 1.5 % horse serum for 60 min. biotinylated anti-mouse IgG (diluted 1:400 in 0.5 M PBS containing 1.5% horse serum) for 30 min, and with avidin-biotin complex or ABC reagent (a mixture of avidin DH solution and biotinylated enzyme, each diluted 1 5 0 with 0.5 M PBS). The horse serum, biotinylated anti-mouse IgG, and ABC complex are reagents in the Vectastain Elite ABC Kit (Vector; Burlingame, CA). After each ofthe above incubations specimens were rinsed carefully in 0. containing 0.25% Tween-20 was then added to the sections and allowed to incubate at RT for 60 min (or alternatively overnight at 4'C). After rinsing well in 0.5 M TBS, the sections were next incubated with rabbit anti-mouse IgG (Dako; Carpenteria, CA) (diluted 1:20 in 0.5 M TBS) for 30 min, rinsed with 0.5 M TBS, incubated with mouse alkaline phosphatase-anti-alkaline phosphatase antibody (APAAP) (Dako; diluted 1:40 in 0.5 M TBS) for 30 min and again rinsed with 0.5 M TBS. Tissues were then immersed in a solution made as follows. Naphthol AS-MX phosphate (20 mg) was dissolved in 2 ml N,N-dimethylformamide and this was added to 100 mlO.1 M Tris buffer, pH 8.2, at 20°C. Next, 0.1 ml of 1 M Levamisole was added to the solution to inhibit endogenous alkaline phosphatase, followed by 100 mg of Fast Blue BB salt. This mixture was stirred for 2 min and then filtered before the sections were immersed. Color development took [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] min. The specimens were then washed well in dHzO and mounted with Fluoromount.
Control ExperLnents for TGFB. Tissues known to be TGFB positive (i.e., human placenta and cord) were fixed in Bouin's solution, embedded in glycol methacrylate, and used as the positive control. Mouse IgG isotype or 0.5 M PBS with 1.5% horse serum was used in place of the primary antibody as the negative control.
Interpretation of Slides. After processing, the coverslips were mounted on glass slides and examined by light microscopy. The cells that contained IUdR/BrdU showed blue nuclear staining, while TGFB was labeled brown. TGFB was localized in the cytoplasm of megakaryocytes and also mtracellularly in a wavy linear pattern along fibrous septae, as a patchy, granular pattern in other areas, and along the basement membranes of blood vessels. Nuclear staining was not observed with TGFB.
Results
For precise in situ localization of TGFB and its relationship to dividing cells, this section will be divided into two major areas.
Single Label Immunohistochemical Staining for Z F B
A variety of human tissues, ranging from bone marrow biopsy spec-imens obtained from leukemia patients to lymphomas, brain, breast, and colon cancers, were studied for immunohistochemical detection of TGFB. Figure 1 demonstrates the major areas of TGFB concentration in a bone marrow biopsy section from an AML patient, described as follows.
Intracellular. The most common cell type showing the presence of TGFB in the cytoplasm belonged to the megakaryocytic lineage (Figures la and Ib) .
Interstitial. Marked brown staining was often noted in the interstitial stromal tissue of the bone marrow biopsy specimens (Figure IC) . The intensity of staining varied from patient to patient.
Vascular. Distinct and highly concentrated label was visible in the basement membrane of the blood vessels ( Figure Id) .
In addition to bone marrows, the solid tumors that were studied showed a variety of labeling patterns. These are shown in Figure  2 for breast (Figures 2a and 2b ), brain (Figures 2c and 2d) , and colon cancers (Figures 2e and 2f ).
Double Labeling for TGFB and IU&/BrdU
To determine the patterns of cell proliferation and their contiguity to TGFB staining, the double label technique was found to be extremely useful. Figures 3a and 3b show the simultaneous detection of both in bone marrow biopsy specimens, while Figures 3c-3h demonstrate the same in breast, brain, and colon cancers. Clearly stained blue nuclei identify the malignant cells engaged in DNA synthesis, while the brown staining represents TGFB. Once again, a diverse assortment of staining patterns was seen in different patients.
Discussion
Given the importance of defining the relationship between expression of growth factors and the behavior of neoplastic cells in their vicinity, a double label method has been described which is reliable and can be performed on plastic-embedded biopsy sections.
The single most useful contribution of this technique is that cells synthesizing DNA can be identified simultaneously in situ along with detection of TGFB. Another advantage is that the entire procedure can be accomplished within 1 day as opposed to other immunohistochemical methods that have been previously described for the detection of "GFB that require two ovemight incubations (7) .
A unique property that frequently characterizes cancer cells is related to their independence of paracrine/autocrine influences exerted through growth factors (8) . The double label technique described here is expected to help distinguish between patients whose cells have indeed acquired an autonomous mechanism of proliferation vs those in whom hormonal influences continue to modulate veloping the ability to identlfy these properties in a reliable manner, we can perhaps select the patients who should be considered for therapeutic trials with these growth factors. For example, it is conceivable that individuals whose cancer cells appear to be autonomous will not respond to exogenously administered growth factors, while those who do not have S-phase cells coexisting with a rapid double label -Unohistochemical technique has been developed which permits concurrent as-sessment of cells synthesizing DNA and expression of TGFB in situ.
Since these studies can be accomplished in plastic-embedded biopsy specimens, we hope to examine a library of archival material that has been collected and preserwd for the past several years. E F B may be the ones who will respond.
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